Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of ...

Orforgliprion caused an average 11% weight loss among overweight and obese people after a year and a half, researchers ...

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore ...

TUESDAY, Sept. 16, 2025 (HealthDay News) — A triple-sized weekly dose of Ozempic works better to help people with obesity ...

The global injection pen market is set to witness a growth rate of 7% in the next 5 years. Rising prevalence of chronic ...

Modular Medical (MODD) announced Institutional Review Board approval to conduct an in-house feasibility study of its next-generation Pivot insulin ...

Microdosing weight loss drugs, a growing global trend, could offer a new gateway solution for obesity for those priced out of the rising costs of drugs like Wegovy and Mounjaro. Weight loss is a major ...

Use of MODD1 on clinicians with Type 1 diabetes SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery tec ...

Persistent high blood sugar in diabetes, despite insulin use, often stems from insulin resistance, where cells fail to respond effectively to the hormone. Factors like excess weight, inactivity, ...

Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Great. I think we can get started, everyone. Kallum Titchmarsh here from the Life Sciences team at Morgan Stanley.

As the World Health Organization (WHO) added a new set of drugs for diabetes to its list of essential medicines on September 5, it was vindication for Pune-based Nupur Lalvani, who was the sole ...

In a medical first, researchers report that they have implanted CRISPR-edited pancreas cells into a person with type 1 diabetes. The cells pumped out sugar-regulating insulin for months — without the ...